← Back to Screener
Repligen Corp (RGEN)
Price$131.99
Favorite Metrics
Price vs S&P 500 (26W)-18.41%
Price vs S&P 500 (4W)5.72%
Market Capitalization$7.42B
P/E Ratio (Annual)151.72x
All Metrics
P/CF (Annual)63.18x
Book Value / Share (Quarterly)$37.39
P/TBV (Annual)5.36x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-2.70%
Cash Flow / Share (Quarterly)$1.63
Price vs S&P 500 (YTD)-24.06%
Gross Margin (TTM)52.65%
Net Profit Margin (TTM)6.62%
EPS (TTM)$0.86
10-Day Avg Trading Volume0.78M
EPS Excl Extra (TTM)$0.86
Revenue Growth (5Y)15.05%
EPS (Annual)$0.86
ROI (Annual)1.85%
Gross Margin (Annual)52.65%
Net Profit Margin (5Y Avg)10.10%
Cash / Share (Quarterly)$13.63
P/E Basic Excl Extra (TTM)151.72x
Revenue Growth QoQ (YoY)18.12%
EPS Growth (5Y)-4.90%
P/E Normalized (Annual)151.72x
ROA (Last FY)1.66%
Revenue Growth TTM (YoY)17.59%
EBITD / Share (TTM)$2.42
ROE (5Y Avg)3.98%
Operating Margin (TTM)7.47%
Cash Flow / Share (Annual)$1.63
P/B Ratio3.52x
P/B Ratio (Quarterly)4.38x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)10.02x
Net Interest Coverage (TTM)13.28x
ROA (TTM)1.68%
EV / EBITDA (TTM)54.08x
EPS Incl Extra (Annual)$0.86
Current Ratio (Annual)8.37x
Quick Ratio (Quarterly)6.82x
3-Month Avg Trading Volume0.77M
52-Week Price Return-0.67%
EV / Free Cash Flow (Annual)80.65x
P/E Incl Extra (TTM)151.72x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$30.54
P/S Ratio (Annual)10.05x
Asset Turnover (Annual)0.25x
52-Week High$175.77
Operating Margin (5Y Avg)12.08%
EPS Excl Extra (Annual)$0.86
CapEx CAGR (5Y)-0.44%
Tangible BV CAGR (5Y)6.73%
26-Week Price Return-9.66%
Quick Ratio (Annual)7.02x
13-Week Price Return-19.02%
Total Debt / Equity (Annual)0.26x
Current Ratio (Quarterly)8.37x
Enterprise Value$7,394.389
Revenue / Share Growth (5Y)13.94%
Asset Turnover (TTM)0.25x
Book Value / Share Growth (5Y)6.03%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.23x
Pretax Margin (Annual)8.45%
Cash / Share (Annual)$13.63
3-Month Return Std Dev42.52%
Gross Margin (5Y Avg)53.29%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)9.82%
EBITDA Interim CAGR (5Y)8.52%
ROE (Last FY)2.32%
Net Interest Coverage (Annual)-3.82x
EPS Basic Excl Extra (Annual)$0.86
P/FCF (TTM)80.91x
Receivables Turnover (TTM)5.04x
EV / Free Cash Flow (TTM)80.65x
Total Debt / Equity (Quarterly)0.26x
EPS Incl Extra (TTM)$0.86
Receivables Turnover (Annual)5.04x
ROI (TTM)1.88%
P/S Ratio (TTM)10.05x
Pretax Margin (5Y Avg)12.66%
Revenue / Share (Annual)$13.05
Tangible BV / Share (Annual)$30.54
Forward P/E67.08x
Free OCF CAGR (5Y)20.36%
Price vs S&P 500 (52W)-35.77%
P/E Ratio (TTM)151.72x
Year-to-Date Return-19.93%
5-Day Price Return7.03%
EPS Normalized (Annual)$0.86
ROA (5Y Avg)2.97%
Net Profit Margin (Annual)6.62%
Month-to-Date Return11.36%
Cash Flow / Share (TTM)$3.18
EBITD / Share (Annual)$2.42
EPS Growth (3Y)-35.59%
Operating Margin (Annual)7.47%
LT Debt / Equity (Annual)0.26x
P/CF (TTM)63.18x
ROI (5Y Avg)3.42%
P/E Excl Extra (TTM)151.72x
LT Debt / Equity (Quarterly)0.26x
EPS Basic Excl Extra (TTM)$0.86
P/TBV (Quarterly)5.36x
P/B Ratio (Annual)4.38x
Inventory Turnover (TTM)2.23x
Pretax Margin (TTM)8.45%
Book Value / Share (Annual)$37.39
Price vs S&P 500 (13W)-21.89%
Net Margin Growth (5Y)-16.54%
Beta1.21x
P/FCF (Annual)80.91x
Revenue / Share (TTM)$13.02
ROE (TTM)2.37%
52-Week Low$109.66
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.07
4.07
4.07
4.07
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RGENRepligen Corp | 10.05x | 17.59% | 52.65% | -4.90% | $131.99 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Repligen develops and sells bioprocessing equipment and supplies for manufacturing biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. The company serves biopharmaceutical companies and contract manufacturers globally with four core product categories: filtration and fluid management (55% of revenue), chromatography (21%), proteins (11%), and process analytics (13%). Revenue is geographically balanced across North America (44%), Europe (37%), and Asia Pacific (19%).